ReviewAmerican journal of respiratory and critical care medicine2015
Update in Lung Cancer 2014.
Review in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2024Review
- Article
- A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.Journal of thoracic disease · 2022Article
- Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal.Journal of translational medicine · 2020Article
- Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells.Oncotarget · 2020Article
- The Nucleolin Antagonist N6L Inhibits LINE1 Retrotransposon Activity in Non-Small Cell Lung Carcinoma Cells.Journal of Cancer · 2020Article
- Towards the Optical Detection of Field Cancerization in the Buccal Mucosa of Patients with Lung Cancer.Translational oncology · 2019Article
- Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells.Scientific reports · 2018Article
- Utilization of lung cancer cell lines for the study of lung cancer stem cells.Oncology letters · 2018Review
- LINE-1 couples EMT programming with acquisition of oncogenic phenotypes in human bronchial epithelial cells.Oncotarget · 2017Article
- Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.Annals of translational medicine · 2017Review
- Lung Cancer Diagnosis by Fine Needle Aspiration Is Associated With Reduction in Resection of Nonmalignant Lung Nodules.The Annals of thoracic surgery · 2017Article
- Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.American journal of respiratory and critical care medicine · 2017Article
- The action and mechanism of myrislignan on A549 cells in vitro and in vivo.Journal of natural medicines · 2017Article
- Smoking and Lung Cancer: A Geo-Regional Perspective.Frontiers in oncology · 2017Review
- The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Article
- Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 CellsBioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.